ConductScience.org, home

Paper39963240

Discovery of novel and highly potent small molecule inhibitors targeting FLT3-ITD for the treatment of acute myeloid leukemia using structure-based virtual screening and biological evaluation.

Shi K and 5 others. Front Pharmacol, 2025. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Discovery of novel and highly potent small molecule inhibitors targeting FLT3-ITD for the treatment of acute myeloid leukemia using structure-based virtual screening and biological evaluation. Papers, record 39963240. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39963240

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Discovery of novel and highly potent small molecule inhibitors targeting FLT3-ITD for the treatment of acute myeloid leukemia using structure-based virtual screening and biological evaluation.
PubMed
Journal
Front Pharmacol
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2025-02-19
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shi KKun
2Hong YYe
3Liu HHuajing
4Yang XXiaotian
5Wang FFengzhen
6Zhang YYanming

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References38

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134045454FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.Blood Cancer J2021https://conductscience.org/library/papers/34045454PubMed
236543880Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia.Leukemia2023https://conductscience.org/library/papers/36543880PubMed
314759363The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.Mol Cell2004https://conductscience.org/library/papers/14759363PubMed
438230766Cancer statistics, 2024.CA Cancer J Clin2024https://conductscience.org/library/papers/38230766PubMed
537892567A Review of FLT3 Kinase Inhibitors in AML.J Clin Med2023https://conductscience.org/library/papers/37892567PubMed
634497236[FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia].Rinsho Ketsueki2021https://conductscience.org/library/papers/34497236PubMed
738182819FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia.Leukemia2024https://conductscience.org/library/papers/38182819PubMed
833619261Acute myeloid leukemia: current progress and future directions.Blood Cancer J2021https://conductscience.org/library/papers/33619261PubMed
932722298Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.Biomedicines2020https://conductscience.org/library/papers/32722298PubMed
1020705759FLT3 as a therapeutic target in AML: still challenging after all these years.Blood2010https://conductscience.org/library/papers/20705759PubMed
1125826077FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.Oncotarget2015https://conductscience.org/library/papers/25826077PubMed
1232021432Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date.Cancer Manag Res2020https://conductscience.org/library/papers/32021432PubMed
1331821677FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.Cancer Sci2020https://conductscience.org/library/papers/31821677PubMed
1431919472FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.Leukemia2020https://conductscience.org/library/papers/31919472PubMed
1530651634Targeting FLT3 mutations in AML: review of current knowledge and evidence.Leukemia2019https://conductscience.org/library/papers/30651634PubMed
1638917943Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy.Crit Rev Oncol Hematol2024https://conductscience.org/library/papers/38917943PubMed
1731632141Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection.Cancer Manag Res2019https://conductscience.org/library/papers/31632141PubMed
1838932630A temporal and multinational assessment of acute myeloid leukemia (AML) cancer incidence, survival, and disease burden.Leuk Lymphoma2024https://conductscience.org/library/papers/38932630PubMed
1933853292A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.Haematologica2021https://conductscience.org/library/papers/33853292PubMed
2031473943Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study.Int J Hematol2019https://conductscience.org/library/papers/31473943PubMed

See all 38 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42466468FLT3 inhibitors in AML: from classic scaffolds to next-generation approaches.RSC Adv2026https://conductscience.org/library/papers/42466468PubMed
42144504Rational design and comparative docking and simulation of modified FLT3 inhibitors: a study on enhanced binding stability and inhibition potency.J Mol Model2026https://conductscience.org/library/papers/42144504PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
FLT32322PubTator's text mininghttps://conductscience.org/library/genes/2322

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39963240

GET https://conductscience.org/api/papers/v1/39963240/references?page=2